Communiqués Gabather AB

Actions

GABA

SE0010869552

Recherche biotechnologique et médicale

Temps Différé Nasdaq Stockholm 14:07:40 08/10/2026			Varia. 5j.	Varia. 1 janv.
0,0236 ^SEK	-4,07%		-15,71%	-13,87%

31/08	Gabather AB (publ) publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI
29/05	Gabather AB (publ) publie ses résultats pour le premier trimestre clos le 31 mars 2026	CI

Communiqués

07/09	Gabather: Awaiting progress after a quiet summer	AQ
02/06	Gabather: Phase II finally activated	AQ
08/05	Gabather: Starting phase II clinical trial	AQ
19/03	Gabather: Key shareholders show support	AQ
01/12	Gabather: Eager to start the TOTEMS study	AQ
01/09/25	Gabather: TOTEMS-study delayed, not derailed	AQ
19/06/25	Gabather: High potential in specific modulation	AQ
13/01/25	Gabather AB appoints Pareto Securities AB to act as a liquidity provider for the Company's share	AQ
10/04/24	Gabather Joins Forces with the Centre for Neuropsychiatric Schizophrenia Research in Denmark to Conduct a Clinical Phase II Study with GT-002	AQ
18/03/24	Gabather files two new patent applications to secure novel findings on the effects of GT-002 for the treatment of psychiatric disorders	AQ
07/03/24	Gabather reports initial positive results from the EEG/fMRI target engagement study	AQ
22/12/23	Gabather AB receives initial EEG data analysis from the GT-002 target engagement study	AQ
14/12/23	Gabather AB initiates discussions with specialist doctors and researchers at Karolinska Institutet for the design of a study in individuals at risk of developing frontotemporal dementia (FTD)	AQ
11/12/23	Gabather AB broadens the scope of EEG data analysis generated during the target engagement study by partnering with MINDIG	AQ
12/10/23	Gabather Announces Completion of Phase I EEG/fMRI Target Engagement Study of GT-002 in Healthy Volunteers	AQ
13/04/23	Gabather, Receives Notice of Approval from the Japanese Patent Office (JPO) for its National Phase Application No. 2020-554957	AQ
07/06/22	Gabather AB, receives Notice of Allowance from the U.S. Patent Office for its U.S. patent application publication No. US 2021/0087193 A1	AQ
02/06/22	BioStock: Gabather's lead candidate moves forward in the clinic	AQ
17/05/22	Gabather receives approval to start the EEG/fMRI target engagement study with the drug candidate GT-002	AQ
22/03/22	Gabather AB invited by the Alzheimer's Drug Discovery Foundation, USA to submit a grant application to expand the studies with GT-002 in preclinical models of Alzheimer's disease	AQ
14/09/21	BioStock: Gabather poised to complete phase I with GT-002	AQ
10/05/21	BioStock: Covid unmasks need for better mental health medication	AQ
25/03/21	BioStock Studio: Gabather gives clinical trial update	AQ
24/03/21	Gabather : enters into a research collaboration with leading US scientists to investigate GT-002 in a unique preclinical model of Alzheimer's Disease	AQ
22/02/21	BioStock: Q4 report points to progress in the clinic for Gabather	AQ